2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2512

Depot Medroxyprogesterone Acetate Birth Control May Suppress Toll-like Receptor 7-Induced Interferon-Alpha Production By Plasmacytoid Dendritic Cells in Women
Abstract Number: 1811

Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
Abstract Number: 395

Depression Risk Among Adults with Childhood- and Adult-Onset Systemic Lupus Erythematosus: 11 Years of Follow-up
Abstract Number: 2337

Depression, Bad Sleep Quality, and Functional Deficit Are Independently Associated with Persistent Fatigue in Arthritic Patients with Low Disease Activity Under Biological Dmards
Abstract Number: 1967

Deregulation of Interleukin-22 Pathway in Giant Cell Arteritis
Abstract Number: 2332

Deriving ‘population References’ of Health Utilities for Patients with Spondyloarthritis Based on the ASAS Health Index
Abstract Number: 1587

Deriving a Comorbidity Index Form the Meddra Classification: Performance of Rheumatic Disease Comorbidity Index, Charlson-Deyo Index and Functional Comorbidity Index Among Patients with RA in NOR-DMARD Cohort
Abstract Number: 2369

Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: A Longitudinal Analysis
Abstract Number: 2329

Describe Treatments As ‘new’ or ‘old’ at Your Peril: Influences on Patient Decision Making
Abstract Number: 420

Description of the Juvenile Localized Scleroderma Subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 1442

Descriptive Characteristics of Patients Prescribed Opioids for the Treatment of Chronic Pain
Abstract Number: 1198

Design and Implementation of a Patient-Centered Navigator Program to Improve Adherence to Disease-Modifying Antirheumatic Drugs
Abstract Number: 1315

Detecting Subtle Changes in Bone Structure Following Three-Month Anti-TNF Theraphy Using High-Resolution Peripheral Quantitative Computed Tomography
Abstract Number: 1358

Detection of a Unique Viral Infection in Salivary Glands of Sjögren’s Syndrome Patients and Viral-Mediated Recapitulation of Disease in Vivo
Abstract Number: 2397

Detection of Changes in the Serum and Synovial Fluid Levels of Resistin during Flare Ups and Remissions in Primary Knee Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].